Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
利洛妥木单抗联合表柔比星、顺铂和卡培他滨作为MET阳性晚期胃癌或胃食管交界处癌一线治疗方案（RILOMET-1）：一项随机、双盲、安慰剂对照的3期临床试验
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(17)30566-1
Catenacci, Daniel V T; Tebbutt, Niall C; Davidenko, Irina; Murad, André M; Al-Batran, Salah-Eddin; Ilson, David H; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A; Udrea, Anghel A; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang, Rui; Ang, Agnes; Zhang, Yilong; Hoang, Tien; Sidhu, Roger; Cunningham, David
